10-Q quarterly report · filed Nov 12, 2026

Journey Medical Corp (DERM) Q3 2026 10-Q Quarterly Report

Short answer

Journey Medical Corp (DERM) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $19M (up 11.2% year over year) with net income of −$1M.

Q3 2026 key financials · XBRL

Revenue
$19M
+11.2% YoY · +6.1% QoQ
Net income
−$1M
+43.2% YoY · −321.5% QoQ
Operating margin
-2.8%
EPS (diluted)
−$0.05
+44.4% YoY · −400.0% QoQ

Source: XBRL data from the Journey Medical Corp (DERM) Q3 2026 10-Q on SEC EDGAR. USD.

Journey Medical Corp Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $19.0M, up $1.3M YoY, driven by Emrosi sales
  • Operating loss $0.5M vs $1.5M YoY, operating margin -2.8% vs -8.7%
  • Best performer Emrosi: $9.0M, up $4.1M; worst Qbrexza: $5.6M, down $1.8M
  • Cash $22.3M vs $24.1M at December 31, 2025; nine-month operating cash use $2.3M
  • Going-concern uncertainty, potential debt or equity financing needs, generic competition and Qbrexza coverage headwinds

Risk Factors

  • No material changes to risk factors disclosed since the 2025 Form 10-K
  • Carried-forward business risk: unidentified risks may materially adversely affect operations
  • Carried-forward financial risk: risks may materially affect financial condition
  • Carried-forward performance risk: risks may materially affect results of operations

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Journey Medical Corp quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.